Together, these findings suggest that Fe2O3 nanoparticles are indeed capable of reducing the viscoelasticity of the simulated asthmatic AM, most likely through disruption of mucin polymerization, and may hence have great potential to be developed into novel mucolytics for therapeutic clearance of AM in severe asthma. The gene discussed is MUC5AC; the disease is asthma.